Project description
A closer look at post-COVID health risks
The post-acute phase (PAP) of COVID-19 poses an alarming risk for non-communicable diseases (NCDs), regardless of the severity of the acute phase. With up to 70 % of patients experiencing reduced organ function in this phase, over 183 million cases reported in the EU could lead to a surge in NCDs. With this in mind, the EU-funded POINT project is pioneering a comprehensive approach to mitigate PAP risks efficiently. Specifically, it is developing biomarkers, a virtual twin model for clinical support, and guidelines targeting vulnerable groups. With an interdisciplinary consortium and vast European cohorts, POINT promises to revolutionise post-COVID healthcare, anticipating future infectious disease challenges.
Objective
The post-acute phase (PAP) of COVID-19, occurring 4 months after the acute phase, is associated with an increased risk for the development of non-communicable diseases (NCDs). The risk of complications in this phase does not depend on the severity of the acute phase. In the EU, more than 183 million cases of COVID-19 have been reported and up to 70% of patients suffer reduced organ function in the PAP. Our conservative estimate it that 5% of people who have suffered COVID-19 are at risk of developing NCDs of the pulmonary, cardiovascular and renal systems due to the PAP.
To avoid the significant socioeconomic costs related to this burden, POINT will develop knowledge-based biomarkers for prevention and management of NCDs, a virtual twin model that offers clinical decision support, and clinical guidelines and recommendations for the entire health care value chain with special attention to vulnerable groups. We will fulfil an unmet need for knowledge and tools to minimize the risk factors of the PAP at the optimal point in time, when healthcare systems will have to redirect their focus from the acute phase of COVID-19 to the post-acute phase. The outcomes of POINT will aid the health care value chain already from an early phase of the project. Furthermore, POINT will correlate and promote knowledge on the development of NCDs in general and the risks of PAP from other infectious diseases.
POINT will meet the challenges with a holistic approach from a truly interdisciplinary consortium consisting of clinical experts, molecular biologists, behavioural scientists, and computer scientists, who will take advantage of cohorts of more than 6 million Europeans, and cross-sectional biobanks from more than 6000 Europeans. Researchers will work together with standardisation experts, an end-user organization representing >120.000 physicians, as well as a dedicated partner for data management ensuring rapid absorption of the outcomes of the project by all stakeholders.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.2.1 - Health
MAIN PROGRAMME
See all projects funded under this programme -
HORIZON.2.1.3 - Non-Communicable and Rare Diseases
See all projects funded under this programme -
HORIZON.2.1.4 - Infectious Diseases, including poverty-related and neglected diseases
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-RIA - HORIZON Research and Innovation Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-HLTH-2023-DISEASE-03
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
1165 KOBENHAVN
Denmark
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.